Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunotherapy

NSCLC Stage IV Clinical Trial

Official title:

A Multicenter, Randomized Controlled Clinical Trial of Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunotherapy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06313541
• Other study ID #: 2024-Lung-LDRT/SBRT
• Status: Recruiting
• Phase: Phase 2
• Start date: April 10, 2024
• Est. completion date: December 31, 2025

Study information

• Verified date: June 2024
• Source: Fudan University
• Contact: Zhengfei Zhu
• Phone: +86-18017312901
• Email: fuscczzf[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a multicenter, randomized controlled clinical trial to explore the preliminary efficacy and safety of treatment response adapted hybrid radiotherapy (LDRT and SBRT) in the first-line treatment of immunotherapy combined with chemotherapy for advanced driver-gene negative NSCLC, and to provide new ideas for the comprehensive treatment of advanced NSCLC

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 146
• Est. completion date: December 31, 2025
• Est. primary completion date: June 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• ECOG functional status score was 0-1.

• Histologically confirmed stage IV primary NSCLC;

• Genetic testing showed that the common driver genes including EGFR, ALK and ROS-1 were negative;

• Patients with brain metastases were eligible if they were neurologically asymptomatic and had stable disease without receiving systemic glucocorticoids;

• According to the investigator's judgment, the patient does not need to receive palliative radiotherapy for any site at present;

• Male/female of childbearing age agreed to use contraception (surgical ligation or oral contraceptive/intrauterine device plus condom) during the trial;

• Life expectancy =3 months;

• One week before enrollment, the organ function level met the following criteria:

? Bone marrow function: hemoglobin =80g/L, white blood cell count =4.0*10^9/L or neutrophil count =1.5*10^9/L, platelet count =100*10^9/L;

? Liver: serum total bilirubin level =1.5 times upper limit of normal, direct bilirubin level must be =1.5 times upper limit of normal, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =2.5 times upper limit of normal;

? Kidney: serum creatinine < 1.5 times upper limit of normal or creatinine clearance =50ml/min, urea nitrogen =200mg/L; Serum albumin =30g/L;

• Patients must be able to understand and voluntarily sign the informed consent form.

Exclusion Criteria:

• The patient had severe autoimmune diseases: active inflammatory bowel disease (including Crohn's disease, ulcerative colitis), rheumatoid arthritis, scleroderma, systemic lupus erythematosus, autoimmune vasculitis (such as Wegener's granulomatosis), etc.

• Symptomatic interstitial lung disease or active infectious/non-infectious pneumonia;

• Patients with risk factors for intestinal perforation: active diverticulitis, intra-abdominal abscess, gastrointestinal (GI) obstruction, abdominal cancer, or other known risk factors for intestinal perforation;

• History of other malignant tumors;

• Patients with active infection, heart failure, myocardial infarction, unstable angina or unstable arrhythmia within the past 6 months;

• Medical examination or clinical findings, or other uncontrollable conditions that the investigator considers may interfere with the results or increase the patient's risk of treatment complications;

• Patients who were considered by the investigator to have lesions requiring palliative and subtractive radiotherapy;

• Mixed with small cell lung cancer components;

• Lactating or pregnant women;

• Congenital or acquired immunodeficiency diseases including human immunodeficiency virus (HIV), organ transplantation or allogeneic stem cell transplantation;

• Known HBV, HCV, active pulmonary tuberculosis infection;

• Patients had received a cancer vaccine or received another vaccine within 4 weeks before starting treatment (note: injectable seasonal influenza vaccine is usually inactivated, so vaccination is allowed, while intranasal vaccine is usually live attenuated, so it is not allowed);

• Patients with concurrent use of other immune agents, chemotherapy drugs, drugs in other clinical studies, and long-term use of cortisol were excluded.

• Patients with mental disorders, substance abuse, or social problems that affect adherence were excluded from the study after physician review;

• Patients who are allergic to or contraindicated to PD-1 monoclonal antibody or chemotherapy drugs.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• NSCLC Stage IV

Intervention

Radiation:
• SBRT or LDRT
Radiotherapy: (1) Low dose radiotherapy (LDRT) : a dose of 2 Gy/1 Fx was given to all visible lesions in the whole body within 1 week before the first course of PD-1/PD-L1 inhibitor combined with chemotherapy (different parts of the lesion could be irradiated separately, but it was required to be completed within 1 week); (2) SBRT: patients received first-line immunotherapy combined with chemotherapy, and their response was evaluated every 6 weeks. Individualized SBRT was planned based on the treatment responses.

Drug:
• PD-1/PD-L1 inhibitor combined with platinum-based chemotherapy
The control group received standard PD-1/PD-L1 inhibitor combined with platinum-based chemotherapy as first-line treatment, and the experimental group received extra treatment response adapted hybrid radiotherapy.

Locations

Country	Name	City	State
China	Fudan University Shanghai Cancer Center	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Fudan University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression Free Survival	The time from enrollment to disease progression or death from any cause. Patients who were still alive at the time of analysis will have the date of their last contact as the cutoff date.	Two years
Secondary	Overall Survival	The time from enrollment to death from any cause. Patients who were still alive at the time of analysis will have the date of their last contact as the cutoff date.	Two years
Secondary	Objective response rate	According to RECISIT1.1 criteria, the proportion of patients achieving CR and PR as their best response before initial disease progression was evaluated.	Two years
Secondary	Progression free survival 2	The time between enrollment and the observation of second disease progression or the occurrence of death from any cause. Patients who were still alive at the time of analysis will have the date of their last contact as the cutoff date.	Two years
Secondary	Treatment-related adverse event	Investigator-assessed treatment-related adverse events were recorded and assessed according to CTCAE5.0	Two years